Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment-Reference-Cited by-同舟云学术

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

Published:2015-10-01 Issue:7 Volume:1 Page:943
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Desmond Andrea¹,Kurian Allison W.²,Gabree Michele¹,Mills Meredith A.²,Anderson Michael J.³,Kobayashi Yuya³,Horick Nora¹,Yang Shan³,Shannon Kristen M.¹,Tung Nadine⁴,Ford James M.²,Lincoln Stephen E.³,Ellisen Leif W.⁵

Affiliation:

1. Massachusetts General Hospital Cancer Center, Boston

2. Stanford University School of Medicine, Stanford, California

3. Invitae Corporation, San Francisco, California

4. Beth Israel Deaconess Medical Center, Boston, Massachusetts5Harvard Medical School, Boston, Massachusetts

5. Massachusetts General Hospital Cancer Center, Boston5Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models;JAMA Network Open;2024-09-09

2. Multi‐gene panel analysis in BRCA1/2‐negative patients suspected of hereditary breast and ovarian cancer syndrome: Real‐world data from a single institution;Journal of Obstetrics and Gynaecology Research;2024-07-30

3. Protocolo sobre el rol del asesoramiento genético oncológico en el marco de oncología de precisión;Oncología Clínica;2024-04-15

4. Family health beliefs and cascade genetic testing in Asian families with hereditary cancer risk: “Okay, now what?”;Journal of Genetic Counseling;2024-03-19

5. Association between missense variants of uncertain significance in the CHEK2 gene and hereditary breast cancer: a cosegregation and bioinformatics analysis;Frontiers in Genetics;2024-02-27